Article Text
Electronic pages
Correspondence response
Tocilizumab in recent polymyalgia rheumatica: how can we manage the interleukin-6 blockage?
Statistics from Altmetric.com
Thanks to Dr Moiseev et al1 for their very interesting opinions on the treatment of polymyalgia rheumatica (PMR) with tocilizumab (TCZ). In the TENOR study,2 for the first time, treatment other than glucocorticoid (GC) was able to control PMR. All patients received TCZ alone during 24 weeks. All parameters were improved: clinical symptoms, biological inflammation, patient's evaluation on disease activity, quality of life and imaging procedure.3 This highlighted the role of interleukin-6 (IL-6) in the pathogenesis of the PMR and probably in giant cell arteritis. IL-6 was first described for its role in adaptive immunity but it also plays a …
Linked Articles
- Electronic pages